sunbet

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
¼±ÐÔÉöË¥½ßÄ£×Ó
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > ÃÚÄòϵͳģ×Ó > ¼±ÐÔÉöË¥½ßÄ£×Ó

ǰÑÔ

¼±ÐÔÉöË¥½ß(acute renal failure,AFR)ÊÇÖ¸ÓÉÓÚÖÖÖÖÔµ¹ÊÔ­ÓÉÒýÆðµÄÉö¹¦Ð§¼±¾çϽµµÄÁÙ´²×ÛºÏÕ÷£¬ÊôÁÙ´²Î£ÖØÖ¢¡£ÉöÉøÍ¸¹¦Ð§ÔÚ¶ÌÆÚÄÚѸËÙ¼õÍË£¬ÉöСÇòÂ˹ý¹¦Ð§Ï½µ£¬BUN¼°CrѸËÙÉý¸ß£¬²¢ÒýÆðË®¡¢µç½âÖʼ°Ëá¼îƽºâʧЭµ÷¼±ÐÔÄò¶¾Ö¢µÈÕ÷Ïó¡£ÏÁÒåµÄ¼±ÐÔÉöË¥½ßÊÇÖ¸¼±ÐÔÉöС¹Ü»µËÀ¡£¹ãÒåµÄARF°´²¡Òò¿É·ÖΪÈýÖÖ£ºÉöǰÐÔ¡¢ÉöºóÐÔ¡¢ÉöʵÖÊÐÔ¼±ÐÔÉöË¥½ß¡£°´ÁÙ´²ÌåÏÖARFÓÖ¿É·ÖΪÉÙÄòÐÍÓë·ÇÉÙÄòÐÍÒÔ¼°¸ßÆÊÎöÐÍ£¬×¡Ôº»¼Õß¼±ÐÔÉöË¥½ßµÄ·¢²¡ÂÊԼΪ5%£¬²¡ËÀÂʸߴï50£¥×óÓÒ¡£¶¯ÎïÄ£×Ó¶à½ÓÄɼÒÍú;ÞϸÊó£¬Óû¯Ñ§ÎïÖÊ»òÕßÊÖÊõÒªÁìÓÕ·¢ÏìÓ¦Ö¢×´¡£

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯Î´óÊó

¡¾ÔìÄ£»úÖÆ¡¿£º

ÓÍËá(oleic acid)ÊÇÒ»ÖÖ¾ßÓнÏÇ¿¶¾ÐÔ×÷ÓõÄÖ¬·¾Ëᣬ×óÉö¶¯Âö×¢ÉäÓÍËáºó£¬ÒýÆðÉöС¹ÜÉÏÆ¤Ï¸°ûÖ×ÕÍ¡¢»µËÀ£¬¼äÖÊË®Ö×£¬ÉöÄÚѪ¹ÜȱѪ£¬Éö΢ѭ»·ÑÏÖØÕϰ­£¬ÉöÔàÉøÍ¸¹¦Ð§Ë¥½ß£¬ÐγÉAFR¡£

¡¾ÔìÄ£ÒªÁì¡¿£º

1.WistarÐÛÐÔ´óÊó£¬ÌåÖØ180~250g¡£ÓÍËá¡¢äå´ú±½¼°ÂÈ»¯Èý±½»ùËĵªßò(triphenyl tetrazolium hloride,TTC)¡£½«´óÊóËæ»ú·Ö³É5×飬ÐÄÀíÑÎË®±ÈÕÕ×飨×óÉö¶¯Âö×¢ÉäÐÄÀíÑÎË®0.45ml/kg£©ÓÍËá¢ñ×é¡¢ÓÍËá¢ò×é¡¢ÓÍËá¢ó×é¡¢ÓÍËá¢ô×飬ʵÑé×éµÄ´óÊó×óÉö¶¯Âö»®·Ö×¢ÉäÓÍËá0.05ml/kg¡¢0.1ml/kg, 0.125ml/kg¡¢0.15ml/kg¡£ÎªÁËÈ·±£×¢ÉäÓÍËáʱ¼ÁÁ¿µÄ׼ȷ£¬ÓÃÖ²ÎïÓÍÏ¡ÊÍÓÍËá¡£Ô¤ÊÔЧ¹ûÅú×¢£¬´¿´âÖ²ÎïÓÍ×é(0.45ml/kg)ÓëÐÄÀíÑÎË®×éÎÞÏÔ×Ųî±ð¡£

2.×óÉö¶¯Âö×¢ÉäÓÍËáºó10·ÖÖÓ¡¢6Сʱ¼°24Сʱ»®·ÖÈ¡²Ä£¬ÓÃTTCȾɫÊÖÒÕÊÓ²ìÉöTTCÏÔÉ«µÄ¸Ä±ä¡£Í¨ÀýÖÆ±¸µç¾µ¼°¹â¾µÇÐÆ¬£¬ÓÃ400T͸Éäµç¾µÊÓ²ìÉöСÇò¼°ÉöС¹ÜÖÜΧëϸѪ¹ÜµÄ³¬Î¢½á¹¹¡£Ôڹ⾵Ï£¬Ã¿ÕÅÇÐÆ¬ÊÓ²ì10¸ö¸ß±¶ÊÓÒ°£¬Í¬Ê±¶ÔÉöС¹Ü»µËÀ¼°ÉöС¹Ü¹ÜÐÍÒÔ0¸ö/HPΪ£¨£­)¡¢1~2¸ö/HPΪ£¨£«£©¡¢3~4¸ö£¯HPΪ(++£©¡¢>4¸öHPΪ£¨£«£«£«£©¾ÙÐмÆÊý£¬¶ÔÓÒÉö¡¢·Î¡¢ÐÄ¡¢ÄÔ¡¢¸Î¡¢Ð¡³¦¡¢ØºÍèÒ²¾ÙÐй⾵ÊӲ졣

3.ÓÃ×迹·¨Ãè¼Ç×óÉö¶¯Âö×¢ÉäÓÍËáºó10·ÖÖÓ¡¢1Сʱ¼°6Сʱ×óÉöÈÝ»ýÂö²¨µÄת±ä¡£×¢ÉäÓÍËá24Сʱºó²â¶¨BUNºÍCr¡£

¡¾Ä£×ÓÌØµã¡¿£º

1.×¢ÉäÓÍËáºó£¬Éö΢ѭ»·±¬·¢ÑÏÖØÕϰ­£¬ÉöСÇòÂ˹ýºÍÉöС¹ÜÉøÍ¸¡¢ÖØÎüÊÕ¹¦Ð§¾ùÊܵ½ËðÉË£¬ÒýÆðÉöÔàÉøÍ¸¹¦Ð§Ë¥½ß¡£×óÉö¶¯Âö×¢ÉäÓÍËá0.15ml/ kgºó10·ÖÖÓ£¬ÉöСÇòëϸѪ¹ÜÄÚÆ¤Ï¸°û½çÏß²»Ç壬ºËȾɫÖʸ߶ÈȺ¼¯³ÊÍÅ¿é×´£¬ºËĤ²¿·ÖÏûÊÅ£¬ÏßÁ£ÌåÖ×ÕÍ£¬»ùµ×Ĥ¾Ö²¿Ôöºñ¡£×¢Éäºó6Сʱ£¬ÉÏÊö¸Ä±ä¼ÓÖØ£¬¿É¼ûÄÚÆ¤Ï¸°ûºËËéÁÑ£¬ÑÏÖØÕ߿ɼûÄÚÆ¤Ï¸°û±À½â¡£ÓÍËá×¢Éäºó24Сʱ£¬ÉöСÇòëϸѪ¹ÜÄÚÆ¤Ï¸°ûºË¹ÌËõ¡¢ºËËéÁÑ¡¢ºËÏûÈÚ£¬ÄÚÆ¤Ï¸°û±À½â£¬»ùµ×Ä¤ÆÆËð¡£

2.Éö×éÖ¯½á¹¹µÄ¸Ä±äÓë×¢ÉäÓÍËáµÄ¼ÁÁ¿Ïà¹Ø¡£ÓÍËá¢ñ~¢ô×é¿É¼ûÉöС¹Ü»µËÀ£¬ÓÍËá¢ò~¢ô×éÓֿɼûÉöСÇòÖ×ÕÍ£¬ÉõÖÁÉöСÇòϸ°ûºËÏûÊÅ£¬°ûÖʺìȾ£¬½á¹¹ÆÆËð£¬ÆäË®Æ½Ëæ×¢ÉäÓÍËá¼ÁÁ¿µÄ¼Ó´ó¶ø¼ÓÖØ¡£×óÉöTTCÏÔÉ«ºó³Ê²Ò°×É«£¬ÓëÓÍËá×÷ÓÃʱ¼äÓйØ£¬ÒÀ×¢ÉäÓÍËá¼ÁÁ¿µÄ²î±ð¶øÓÐÇø±ð£¬¶ø¸÷×éÓÒÉöÏÔʾÏʺìÉ«¡£ÏÔÉ«ÓëÑôÐÔÕß³ÊÔîÐÔ²»ÏÔÉ«²Ò°×Çø£¬¶àÂþÑÜÓÚÆ¤Öʼ°ÍâËèÖÊ£¬ÑÏÖØÕßÀÛ¼°Õû¸öÉöÇÐÃæ¡£

3.×迹ʽÉöÈÝ»ýÂö²¨ÔÚ×¢ÉäÓÍËáºó10·ÖÖÓ¡¢1Сʱ¼°6Сʱ¾ù¿É¼ûµÍƽ¼°Æ½¶¥²¨£¬²¨¸ß»®·ÖΪעǰµÄ34%¡¢32%¡¢32%£¬±È±ÈÕÕ×é½µµÍÁË65%¡¢68£¥¼°66%£¬Åú×¢ÉöÄÚ¶¯ÂöѪ¹Üµ¯ÐÔ½µµÍ£¬Ö÷Òª¶ÈÔö¸ß£¬ÖÜΧ×èÁ¦ÔöÌí£¬Éö×é֯ѪҺ¹àÁ÷Á¿ÏÔ×ÅïÔÌ­¡£ÑªÇåBUNÖµÒÀ×¢ÉäÓÍËá¼ÁÁ¿µÄ²î±ð¶øÓвî±ð¡£ÓÍËá¢ô×éÏÔןßÓÚÆäËû¸÷×é¡£¸÷×é¼äѪÇåCrÎÞÏÔ×Ųî±ð¡£

¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º

±¾Ä£×ÓÊÇÒÔÑÏÖØµÄÉö΢ѭ»·Õϰ­ÎªÌص㣬ºÏ²¢¼äÖÊ¡¢ÊµÖÊËðÉË£¬¿ÉÓÃÓÚÄ£ÄâÈËÀàÆðÔ´ÓÚÉö΢ѭ»·Õϰ­µÄARF¡£×î³£ÓõÄARFʵÑ鶯ÎïÄ£×ÓÓÐÎåÖÖ£ºÉö¶¯Âö¼Ð±Õ¡¢Éö¶¯ÂöÖ±½ÓÊäעȥ¼×ÉöÉÏÏÙËØ¡¢¸ÊÓͼ¡×¢¡¢ÂÈ»¯¹¯¼°ÏõËáÓ˾²Âö×¢Éä¡£ÕâЩģ×Ó¶àÓÃÓÚʵÖÊϸ°û·½ÃæµÄÑо¿¡£±¾Ä£×Ó´Ó×óÉö¶¯Âö×¢ÉäÓÍËáÒýÆðÉö΢ѭ»·¼°ÊµÖÊϸ°ûµÄËðÉË£¬½¨ÉèµÄ´óÊóARFÄ£×ÓÓëÉÏÊöÎåÖÖÄ£×Ó½ÏÁ¿£¬±¾Ä£×ÓÊǵ¥²àÉö΢ѭ»·Õϰ­ÎªÖ÷ºÏ²¢ÉöʵÖÊÑÏÖØËðÉ˵ÄÒ»ÖÖеÄARFÄ£×Ó£¬¿ÉÓÃÓÚÑо¿¼±ÐÔÉöË¥½ß·¢²¡»úÖÆºÍÖÎÁÆÒªÁì¡£

 

²Î¿¼ÎÄÏ×£º

1.ÁõÏ裬ÕŰ×Óñ£¬ÍõÈÙ£®ËÄÖÖ¼±ÐÔÉöË¥½ßÄ£×ÓµÄÖÆ×÷ÓëÌå»á£®ÊµÑ鶯Îï¿ÆÑ§£¬2009,26(4):16-19

2.ɳ³¯êÍ£¬¸¶Æ½£¬ÖÜÀò£¬µÈ£®´óÊó5/6ÉöÇгýÂýÐÔÉöË¥½ß¶¯ÎïÄ£×ÓµÄʵÑéÑо¿£®ËÄ´¨¶¯Î2006, 25 (3):632-635

3.Öܾ²£¬°®Ãñ£¬ÍõÏòÑô£¬µÈ£®ÏÙàÑßÊÖÆ×÷ÂýÐÔÉöË¥½ß´óÊó¼²²¡Ä£×Ó£®ÄÚÃɹÅҽѧԺѧ±¨£¬2004,26 (4):248-249

4.ÕÔº£Ï¼. Ç嵪¹à³¦Òº¶ÔÏÙàÑßÊËùÖ´óÊóÂýÐÔÉöË¥½ßÄ£×ÓµÄÓ°Ï죮ÖйúÖÐÎ÷ҽ͎áÉö²¡ÔÓÖ¾£¬2004,5(11): 634-636

5.ÐìÓ¦³¼£¬ÕÅÐñ£¬ÕÅ´äÞ±£¬µÈ.L£­Èâ¶¾¼î¶ÔÇì´óÃ¹ËØÒýÆðµÄ¼±ÐÔÉöË¥½ßµÄ±£»¤×÷ÓÃÑо¿£®ÖйúÒ½Ò©µ¼±¨£¬2012, 9(7):28-29

6.Siegler RL,Pysher TJ,Tesh VL,et al. Response to single and divided doses of Shiga toxin in a primate model of hemolytic uremic syndrome. J Am Soc Nephrol,2001, 12(7):1458-1467

7. Stockel man MG, Lorenz JN, Smith FN, el al. Chronic renal failure in a mouse model of human adenine phosphoribosyltransferase deficiency. Am J Physiol,1998,275 (1 Pt 2): F154-163

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Ä£×ÓĿ¼
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > ÃÚÄòϵͳģ×Ó > ¼±ÐÔÉöË¥½ßÄ£×Ó
¼±ÐÔÉöË¥½ßÄ£×Ó

ǰÑÔ

¼±ÐÔÉöË¥½ß(acute renal failure,AFR)ÊÇÖ¸ÓÉÓÚÖÖÖÖÔµ¹ÊÔ­ÓÉÒýÆðµÄÉö¹¦Ð§¼±¾çϽµµÄÁÙ´²×ÛºÏÕ÷£¬ÊôÁÙ´²Î£ÖØÖ¢¡£ÉöÉøÍ¸¹¦Ð§ÔÚ¶ÌÆÚÄÚѸËÙ¼õÍË£¬ÉöСÇòÂ˹ý¹¦Ð§Ï½µ£¬BUN¼°CrѸËÙÉý¸ß£¬²¢ÒýÆðË®¡¢µç½âÖʼ°Ëá¼îƽºâʧЭµ÷¼±ÐÔÄò¶¾Ö¢µÈÕ÷Ïó¡£ÏÁÒåµÄ¼±ÐÔÉöË¥½ßÊÇÖ¸¼±ÐÔÉöС¹Ü»µËÀ¡£¹ãÒåµÄARF°´²¡Òò¿É·ÖΪÈýÖÖ£ºÉöǰÐÔ¡¢ÉöºóÐÔ¡¢ÉöʵÖÊÐÔ¼±ÐÔÉöË¥½ß¡£°´ÁÙ´²ÌåÏÖARFÓÖ¿É·ÖΪÉÙÄòÐÍÓë·ÇÉÙÄòÐÍÒÔ¼°¸ßÆÊÎöÐÍ£¬×¡Ôº»¼Õß¼±ÐÔÉöË¥½ßµÄ·¢²¡ÂÊԼΪ5%£¬²¡ËÀÂʸߴï50£¥×óÓÒ¡£¶¯ÎïÄ£×Ó¶à½ÓÄɼÒÍú;ÞϸÊó£¬Óû¯Ñ§ÎïÖÊ»òÕßÊÖÊõÒªÁìÓÕ·¢ÏìÓ¦Ö¢×´¡£

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯Î´óÊó

¡¾ÔìÄ£»úÖÆ¡¿£º

ÓÍËá(oleic acid)ÊÇÒ»ÖÖ¾ßÓнÏÇ¿¶¾ÐÔ×÷ÓõÄÖ¬·¾Ëᣬ×óÉö¶¯Âö×¢ÉäÓÍËáºó£¬ÒýÆðÉöС¹ÜÉÏÆ¤Ï¸°ûÖ×ÕÍ¡¢»µËÀ£¬¼äÖÊË®Ö×£¬ÉöÄÚѪ¹ÜȱѪ£¬Éö΢ѭ»·ÑÏÖØÕϰ­£¬ÉöÔàÉøÍ¸¹¦Ð§Ë¥½ß£¬ÐγÉAFR¡£

¡¾ÔìÄ£ÒªÁì¡¿£º

1.WistarÐÛÐÔ´óÊó£¬ÌåÖØ180~250g¡£ÓÍËá¡¢äå´ú±½¼°ÂÈ»¯Èý±½»ùËĵªßò(triphenyl tetrazolium hloride,TTC)¡£½«´óÊóËæ»ú·Ö³É5×飬ÐÄÀíÑÎË®±ÈÕÕ×飨×óÉö¶¯Âö×¢ÉäÐÄÀíÑÎË®0.45ml/kg£©ÓÍËá¢ñ×é¡¢ÓÍËá¢ò×é¡¢ÓÍËá¢ó×é¡¢ÓÍËá¢ô×飬ʵÑé×éµÄ´óÊó×óÉö¶¯Âö»®·Ö×¢ÉäÓÍËá0.05ml/kg¡¢0.1ml/kg, 0.125ml/kg¡¢0.15ml/kg¡£ÎªÁËÈ·±£×¢ÉäÓÍËáʱ¼ÁÁ¿µÄ׼ȷ£¬ÓÃÖ²ÎïÓÍÏ¡ÊÍÓÍËá¡£Ô¤ÊÔЧ¹ûÅú×¢£¬´¿´âÖ²ÎïÓÍ×é(0.45ml/kg)ÓëÐÄÀíÑÎË®×éÎÞÏÔ×Ųî±ð¡£

2.×óÉö¶¯Âö×¢ÉäÓÍËáºó10·ÖÖÓ¡¢6Сʱ¼°24Сʱ»®·ÖÈ¡²Ä£¬ÓÃTTCȾɫÊÖÒÕÊÓ²ìÉöTTCÏÔÉ«µÄ¸Ä±ä¡£Í¨ÀýÖÆ±¸µç¾µ¼°¹â¾µÇÐÆ¬£¬ÓÃ400T͸Éäµç¾µÊÓ²ìÉöСÇò¼°ÉöС¹ÜÖÜΧëϸѪ¹ÜµÄ³¬Î¢½á¹¹¡£Ôڹ⾵Ï£¬Ã¿ÕÅÇÐÆ¬ÊÓ²ì10¸ö¸ß±¶ÊÓÒ°£¬Í¬Ê±¶ÔÉöС¹Ü»µËÀ¼°ÉöС¹Ü¹ÜÐÍÒÔ0¸ö/HPΪ£¨£­)¡¢1~2¸ö/HPΪ£¨£«£©¡¢3~4¸ö£¯HPΪ(++£©¡¢>4¸öHPΪ£¨£«£«£«£©¾ÙÐмÆÊý£¬¶ÔÓÒÉö¡¢·Î¡¢ÐÄ¡¢ÄÔ¡¢¸Î¡¢Ð¡³¦¡¢ØºÍèÒ²¾ÙÐй⾵ÊӲ졣

3.ÓÃ×迹·¨Ãè¼Ç×óÉö¶¯Âö×¢ÉäÓÍËáºó10·ÖÖÓ¡¢1Сʱ¼°6Сʱ×óÉöÈÝ»ýÂö²¨µÄת±ä¡£×¢ÉäÓÍËá24Сʱºó²â¶¨BUNºÍCr¡£

¡¾Ä£×ÓÌØµã¡¿£º

1.×¢ÉäÓÍËáºó£¬Éö΢ѭ»·±¬·¢ÑÏÖØÕϰ­£¬ÉöСÇòÂ˹ýºÍÉöС¹ÜÉøÍ¸¡¢ÖØÎüÊÕ¹¦Ð§¾ùÊܵ½ËðÉË£¬ÒýÆðÉöÔàÉøÍ¸¹¦Ð§Ë¥½ß¡£×óÉö¶¯Âö×¢ÉäÓÍËá0.15ml/ kgºó10·ÖÖÓ£¬ÉöСÇòëϸѪ¹ÜÄÚÆ¤Ï¸°û½çÏß²»Ç壬ºËȾɫÖʸ߶ÈȺ¼¯³ÊÍÅ¿é×´£¬ºËĤ²¿·ÖÏûÊÅ£¬ÏßÁ£ÌåÖ×ÕÍ£¬»ùµ×Ĥ¾Ö²¿Ôöºñ¡£×¢Éäºó6Сʱ£¬ÉÏÊö¸Ä±ä¼ÓÖØ£¬¿É¼ûÄÚÆ¤Ï¸°ûºËËéÁÑ£¬ÑÏÖØÕ߿ɼûÄÚÆ¤Ï¸°û±À½â¡£ÓÍËá×¢Éäºó24Сʱ£¬ÉöСÇòëϸѪ¹ÜÄÚÆ¤Ï¸°ûºË¹ÌËõ¡¢ºËËéÁÑ¡¢ºËÏûÈÚ£¬ÄÚÆ¤Ï¸°û±À½â£¬»ùµ×Ä¤ÆÆËð¡£

2.Éö×éÖ¯½á¹¹µÄ¸Ä±äÓë×¢ÉäÓÍËáµÄ¼ÁÁ¿Ïà¹Ø¡£ÓÍËá¢ñ~¢ô×é¿É¼ûÉöС¹Ü»µËÀ£¬ÓÍËá¢ò~¢ô×éÓֿɼûÉöСÇòÖ×ÕÍ£¬ÉõÖÁÉöСÇòϸ°ûºËÏûÊÅ£¬°ûÖʺìȾ£¬½á¹¹ÆÆËð£¬ÆäË®Æ½Ëæ×¢ÉäÓÍËá¼ÁÁ¿µÄ¼Ó´ó¶ø¼ÓÖØ¡£×óÉöTTCÏÔÉ«ºó³Ê²Ò°×É«£¬ÓëÓÍËá×÷ÓÃʱ¼äÓйØ£¬ÒÀ×¢ÉäÓÍËá¼ÁÁ¿µÄ²î±ð¶øÓÐÇø±ð£¬¶ø¸÷×éÓÒÉöÏÔʾÏʺìÉ«¡£ÏÔÉ«ÓëÑôÐÔÕß³ÊÔîÐÔ²»ÏÔÉ«²Ò°×Çø£¬¶àÂþÑÜÓÚÆ¤Öʼ°ÍâËèÖÊ£¬ÑÏÖØÕßÀÛ¼°Õû¸öÉöÇÐÃæ¡£

3.×迹ʽÉöÈÝ»ýÂö²¨ÔÚ×¢ÉäÓÍËáºó10·ÖÖÓ¡¢1Сʱ¼°6Сʱ¾ù¿É¼ûµÍƽ¼°Æ½¶¥²¨£¬²¨¸ß»®·ÖΪעǰµÄ34%¡¢32%¡¢32%£¬±È±ÈÕÕ×é½µµÍÁË65%¡¢68£¥¼°66%£¬Åú×¢ÉöÄÚ¶¯ÂöѪ¹Üµ¯ÐÔ½µµÍ£¬Ö÷Òª¶ÈÔö¸ß£¬ÖÜΧ×èÁ¦ÔöÌí£¬Éö×é֯ѪҺ¹àÁ÷Á¿ÏÔ×ÅïÔÌ­¡£ÑªÇåBUNÖµÒÀ×¢ÉäÓÍËá¼ÁÁ¿µÄ²î±ð¶øÓвî±ð¡£ÓÍËá¢ô×éÏÔןßÓÚÆäËû¸÷×é¡£¸÷×é¼äѪÇåCrÎÞÏÔ×Ųî±ð¡£

¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º

±¾Ä£×ÓÊÇÒÔÑÏÖØµÄÉö΢ѭ»·Õϰ­ÎªÌص㣬ºÏ²¢¼äÖÊ¡¢ÊµÖÊËðÉË£¬¿ÉÓÃÓÚÄ£ÄâÈËÀàÆðÔ´ÓÚÉö΢ѭ»·Õϰ­µÄARF¡£×î³£ÓõÄARFʵÑ鶯ÎïÄ£×ÓÓÐÎåÖÖ£ºÉö¶¯Âö¼Ð±Õ¡¢Éö¶¯ÂöÖ±½ÓÊäעȥ¼×ÉöÉÏÏÙËØ¡¢¸ÊÓͼ¡×¢¡¢ÂÈ»¯¹¯¼°ÏõËáÓ˾²Âö×¢Éä¡£ÕâЩģ×Ó¶àÓÃÓÚʵÖÊϸ°û·½ÃæµÄÑо¿¡£±¾Ä£×Ó´Ó×óÉö¶¯Âö×¢ÉäÓÍËáÒýÆðÉö΢ѭ»·¼°ÊµÖÊϸ°ûµÄËðÉË£¬½¨ÉèµÄ´óÊóARFÄ£×ÓÓëÉÏÊöÎåÖÖÄ£×Ó½ÏÁ¿£¬±¾Ä£×ÓÊǵ¥²àÉö΢ѭ»·Õϰ­ÎªÖ÷ºÏ²¢ÉöʵÖÊÑÏÖØËðÉ˵ÄÒ»ÖÖеÄARFÄ£×Ó£¬¿ÉÓÃÓÚÑо¿¼±ÐÔÉöË¥½ß·¢²¡»úÖÆºÍÖÎÁÆÒªÁì¡£

 

²Î¿¼ÎÄÏ×£º

1.ÁõÏ裬ÕŰ×Óñ£¬ÍõÈÙ£®ËÄÖÖ¼±ÐÔÉöË¥½ßÄ£×ÓµÄÖÆ×÷ÓëÌå»á£®ÊµÑ鶯Îï¿ÆÑ§£¬2009,26(4):16-19

2.ɳ³¯êÍ£¬¸¶Æ½£¬ÖÜÀò£¬µÈ£®´óÊó5/6ÉöÇгýÂýÐÔÉöË¥½ß¶¯ÎïÄ£×ÓµÄʵÑéÑо¿£®ËÄ´¨¶¯Î2006, 25 (3):632-635

3.Öܾ²£¬°®Ãñ£¬ÍõÏòÑô£¬µÈ£®ÏÙàÑßÊÖÆ×÷ÂýÐÔÉöË¥½ß´óÊó¼²²¡Ä£×Ó£®ÄÚÃɹÅҽѧԺѧ±¨£¬2004,26 (4):248-249

4.ÕÔº£Ï¼. Ç嵪¹à³¦Òº¶ÔÏÙàÑßÊËùÖ´óÊóÂýÐÔÉöË¥½ßÄ£×ÓµÄÓ°Ï죮ÖйúÖÐÎ÷ҽ͎áÉö²¡ÔÓÖ¾£¬2004,5(11): 634-636

5.ÐìÓ¦³¼£¬ÕÅÐñ£¬ÕÅ´äÞ±£¬µÈ.L£­Èâ¶¾¼î¶ÔÇì´óÃ¹ËØÒýÆðµÄ¼±ÐÔÉöË¥½ßµÄ±£»¤×÷ÓÃÑо¿£®ÖйúÒ½Ò©µ¼±¨£¬2012, 9(7):28-29

6.Siegler RL,Pysher TJ,Tesh VL,et al. Response to single and divided doses of Shiga toxin in a primate model of hemolytic uremic syndrome. J Am Soc Nephrol,2001, 12(7):1458-1467

7. Stockel man MG, Lorenz JN, Smith FN, el al. Chronic renal failure in a mouse model of human adenine phosphoribosyltransferase deficiency. Am J Physiol,1998,275 (1 Pt 2): F154-163

¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿